Supernus Pharmaceuticals Inc. | Mid-cap | Healthcare
$49.00
-1.03%
| Supernus Stock Comparison:
Supernus vs ZoetisSupernus vs Haleon Plc - ADRSupernus vs Regencell BioscienceSupernus vs Alkermes plcSupernus vs Prestige ConsumerSupernus vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 149.8M
Gross Profit 134.1M 89.48%
Operating Income -2.6M -1.73%
Net Income -11.8M -7.89%
EPS (Diluted) $-0.21

Balance Sheet Metrics

Total Assets 1.3B
Total Liabilities 316.6M
Shareholders Equity 1.0B
Debt to Equity 0.31

Cash Flow Metrics

Operating Cash Flow 22.3M
Free Cash Flow 30.3M

Revenue & Profitability Trend

Supernus Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 661.8M 607.5M 667.2M 579.8M 520.4M
Cost of Goods Sold i 77.9M 83.8M 87.2M 75.1M 52.5M
Gross Profit i 583.9M 523.7M 580.0M 504.7M 467.9M
Gross Margin % i 88.2% 86.2% 86.9% 87.1% 89.9%
Operating Expenses
Research & Development i 108.8M 91.6M 74.6M 90.5M 76.0M
Selling, General & Administrative i 321.6M 336.4M 377.2M 304.8M 200.7M
Other Operating Expenses i - - - - -
Total Operating Expenses i 430.4M 428.0M 451.8M 395.2M 276.6M
Operating Income i 75.6M 13.4M 45.6M 79.5M 175.6M
Operating Margin % i 11.4% 2.2% 6.8% 13.7% 33.7%
Non-Operating Items
Interest Income i 16.2M 10.5M 21.7M 10.6M 18.7M
Interest Expense i 0 2.4M 7.1M 23.4M 23.8M
Other Non-Operating Income 6.1M -18.7M 510.0K 6.5M -1.9M
Pre-tax Income i 97.9M 2.8M 60.7M 73.2M 168.6M
Income Tax i 24.0M 1.5M 32.0K 19.8M 41.7M
Effective Tax Rate % i 24.5% 52.5% 0.1% 27.0% 24.7%
Net Income i 73.9M 1.3M 60.7M 53.4M 127.0M
Net Margin % i 11.2% 0.2% 9.1% 9.2% 24.4%
Key Metrics
EBITDA i 172.2M 108.7M 152.8M 122.7M 212.4M
EPS (Basic) i $1.34 $0.02 $1.13 $1.01 $2.41
EPS (Diluted) i $1.32 $0.02 $1.04 $0.98 $2.36
Basic Shares Outstanding i 55100063 54536281 53665143 53099330 52615269
Diluted Shares Outstanding i 55100063 54536281 53665143 53099330 52615269

Income Statement Trend

Supernus Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 69.3M 75.1M 93.1M 203.4M 288.6M
Short-term Investments i 384.3M 179.8M 368.2M 136.2M 133.9M
Accounts Receivable i 142.1M 144.2M 165.5M 148.9M 140.9M
Inventory i 54.3M 77.4M 91.5M 86.0M 48.3M
Other Current Assets 36.1M 16.7M 15.8M 27.0M 18.7M
Total Current Assets i 686.1M 493.1M 734.2M 601.6M 630.4M
Non-Current Assets
Property, Plant & Equipment i 0 0 12.1M 12.3M 22.7M
Goodwill i 756.0M 833.9M 936.5M 1.0B 520.2M
Intangible Assets i 521.9M 599.9M 702.5M 784.7M 364.3M
Long-term Investments - - - - -
Other Non-Current Assets 31.5M 37.5M 39.8M 49.2M 43.2M
Total Non-Current Assets i 682.0M 784.6M 968.4M 1.1B 873.7M
Total Assets i 1.4B 1.3B 1.7B 1.7B 1.5B
Liabilities
Current Liabilities
Accounts Payable i 4.6M 2.0M 10.5M 9.3M 6.1M
Short-term Debt i 6.9M 8.3M 408.8M 6.5M 3.8M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 47.3M 56.4M 38.0M 65.0M 40.0M
Total Current Liabilities i 292.4M 290.2M 688.0M 315.4M 245.1M
Non-Current Liabilities
Long-term Debt i 27.4M 33.2M 36.0M 420.6M 410.6M
Deferred Tax Liabilities i 5.0M 25.0M 49.8M 85.4M 35.2M
Other Non-Current Liabilities 7.6M 7.8M 42.5M 52.0M 68.4M
Total Non-Current Liabilities i 39.9M 66.0M 128.3M 557.9M 514.1M
Total Liabilities i 332.3M 356.2M 816.3M 873.3M 759.2M
Equity
Common Stock i 56.0K 55.0K 54.0K 53.0K 53.0K
Retained Earnings i 556.4M 482.6M 481.2M 379.9M 326.5M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 1.0B 921.5M 886.2M 815.9M 744.9M
Key Metrics
Total Debt i 34.3M 41.5M 444.8M 427.0M 414.3M
Working Capital i 393.7M 202.9M 46.2M 286.2M 385.3M

Balance Sheet Composition

Supernus Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i 73.9M 1.3M 60.7M 53.4M 127.0M
Depreciation & Amortization i 80.4M 84.9M 85.5M 32.6M 18.1M
Stock-Based Compensation i 27.8M 26.8M 17.6M 17.9M 16.6M
Working Capital Changes i 2.9M -11.4M -55.5M 7.5M -36.5M
Operating Cash Flow i 166.2M 88.7M 82.4M 131.0M 145.7M
Investing Activities
Capital Expenditures i -725.0K -551.0K -412.0K -2.0M -3.7M
Acquisitions i - 0 0 -311.7M -298.5M
Investment Purchases i -688.0M -101.6M -407.0M -311.6M -95.9M
Investment Sales i 498.9M 370.9M 190.7M 530.5M 378.4M
Investing Cash Flow i -189.9M 268.7M -216.7M -94.8M -19.9M
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i 0 0 0 800.0K 0
Debt Repayment i 0 -495.5M 0 -138.3M -802.0K
Financing Cash Flow i 12.2M -893.4M -10.5M -130.4M 3.6M
Free Cash Flow i 171.2M 110.5M 116.4M 125.1M 134.7M
Net Change in Cash i -11.5M -535.9M -144.8M -94.3M 129.3M

Cash Flow Trend

Supernus Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 41.54
Forward P/E 25.28
Price to Book 2.52
Price to Sales 4.03
PEG Ratio 3.74

Profitability Ratios

Profit Margin 9.70%
Operating Margin 6.73%
Return on Equity 6.38%
Return on Assets 2.39%

Financial Health

Current Ratio 2.58
Debt to Equity 2.99
Beta 0.78

Per Share Data

EPS (TTM) $1.15
Book Value per Share $18.96
Revenue per Share $11.96

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
supn 2.7B 41.54 2.52 6.38% 9.70% 2.99
Zoetis 65.1B 25.16 13.06 52.77% 27.83% 137.01
Haleon Plc - ADR 41.9B 20.09 5.12 9.38% 13.81% 53.41
Regencell Bioscience 9.6B -2,233.99 1,328.57 -47.77% 0.00% 0.00
Alkermes plc 5.1B 14.95 3.14 23.94% 23.15% 4.47
Prestige Consumer 3.8B 17.92 2.07 12.30% 18.86% 56.91

Financial data is updated regularly. All figures are in the company's reporting currency.